Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati

Nagla Fawzy Miligy Abdel Karim, S. Haider, C. Siegrist, N. Ahmad, A. Zarzour, J. Ying, Z. Yasin, R. Sacher

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Thrombotic Thrombocytopenic Purpura (TTP) is a rare hematologic emergency, congenital or acquired, characterized by ischemic damage of various organs because of platelet aggregation. It is the common name for adults with microangiopathic hemolytic anemia, thrombocytopenia, with or without neurologic or renal abnormalities, and without another etiology; children without renal failure are also described as TTP. Plasma exchange (PE) is the main stay of treatment in combination with steroids and immunosuppressive therapies. The monoclonal antibody against CD20 Rituximab decreases the production of antibodies from B lymphocytes and it is used for antibodies-mediated diseases including TTP. We present our data on retrospective analysis of rituximab in treatment of TTP at University of Cincinnati in a series of 22 patients from 1997 to 2009. Our results showed that PE with immunosuppressive therapy resulted in decreased duration of PE, relapse rate, and increased duration of remission in patients with TTP.

Original languageEnglish (US)
Article number195746
JournalAdvances in Hematology
Volume2013
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Thrombotic Thrombocytopenic Purpura
Plasma Exchange
Immunosuppressive Agents
Hemolytic Anemia
Therapeutics
Platelet Aggregation
Thrombocytopenia
Nervous System
Antibody Formation
Names
Renal Insufficiency
Emergencies
B-Lymphocytes
Steroids
Monoclonal Antibodies
Kidney
Recurrence
Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati. / Abdel Karim, Nagla Fawzy Miligy; Haider, S.; Siegrist, C.; Ahmad, N.; Zarzour, A.; Ying, J.; Yasin, Z.; Sacher, R.

In: Advances in Hematology, Vol. 2013, 195746, 01.12.2013.

Research output: Contribution to journalArticle

Abdel Karim, NFM, Haider, S, Siegrist, C, Ahmad, N, Zarzour, A, Ying, J, Yasin, Z & Sacher, R 2013, 'Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati', Advances in Hematology, vol. 2013, 195746. https://doi.org/10.1155/2013/195746
Abdel Karim, Nagla Fawzy Miligy ; Haider, S. ; Siegrist, C. ; Ahmad, N. ; Zarzour, A. ; Ying, J. ; Yasin, Z. ; Sacher, R. / Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati. In: Advances in Hematology. 2013 ; Vol. 2013.
@article{ce549c3344704a9a9aa1579f795eeff1,
title = "Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati",
abstract = "Thrombotic Thrombocytopenic Purpura (TTP) is a rare hematologic emergency, congenital or acquired, characterized by ischemic damage of various organs because of platelet aggregation. It is the common name for adults with microangiopathic hemolytic anemia, thrombocytopenia, with or without neurologic or renal abnormalities, and without another etiology; children without renal failure are also described as TTP. Plasma exchange (PE) is the main stay of treatment in combination with steroids and immunosuppressive therapies. The monoclonal antibody against CD20 Rituximab decreases the production of antibodies from B lymphocytes and it is used for antibodies-mediated diseases including TTP. We present our data on retrospective analysis of rituximab in treatment of TTP at University of Cincinnati in a series of 22 patients from 1997 to 2009. Our results showed that PE with immunosuppressive therapy resulted in decreased duration of PE, relapse rate, and increased duration of remission in patients with TTP.",
author = "{Abdel Karim}, {Nagla Fawzy Miligy} and S. Haider and C. Siegrist and N. Ahmad and A. Zarzour and J. Ying and Z. Yasin and R. Sacher",
year = "2013",
month = "12",
day = "1",
doi = "10.1155/2013/195746",
language = "English (US)",
volume = "2013",
journal = "Advances in Hematology",
issn = "1687-9104",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Approach to management of thrombotic thrombocytopenic Purpura at University of Cincinnati

AU - Abdel Karim, Nagla Fawzy Miligy

AU - Haider, S.

AU - Siegrist, C.

AU - Ahmad, N.

AU - Zarzour, A.

AU - Ying, J.

AU - Yasin, Z.

AU - Sacher, R.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Thrombotic Thrombocytopenic Purpura (TTP) is a rare hematologic emergency, congenital or acquired, characterized by ischemic damage of various organs because of platelet aggregation. It is the common name for adults with microangiopathic hemolytic anemia, thrombocytopenia, with or without neurologic or renal abnormalities, and without another etiology; children without renal failure are also described as TTP. Plasma exchange (PE) is the main stay of treatment in combination with steroids and immunosuppressive therapies. The monoclonal antibody against CD20 Rituximab decreases the production of antibodies from B lymphocytes and it is used for antibodies-mediated diseases including TTP. We present our data on retrospective analysis of rituximab in treatment of TTP at University of Cincinnati in a series of 22 patients from 1997 to 2009. Our results showed that PE with immunosuppressive therapy resulted in decreased duration of PE, relapse rate, and increased duration of remission in patients with TTP.

AB - Thrombotic Thrombocytopenic Purpura (TTP) is a rare hematologic emergency, congenital or acquired, characterized by ischemic damage of various organs because of platelet aggregation. It is the common name for adults with microangiopathic hemolytic anemia, thrombocytopenia, with or without neurologic or renal abnormalities, and without another etiology; children without renal failure are also described as TTP. Plasma exchange (PE) is the main stay of treatment in combination with steroids and immunosuppressive therapies. The monoclonal antibody against CD20 Rituximab decreases the production of antibodies from B lymphocytes and it is used for antibodies-mediated diseases including TTP. We present our data on retrospective analysis of rituximab in treatment of TTP at University of Cincinnati in a series of 22 patients from 1997 to 2009. Our results showed that PE with immunosuppressive therapy resulted in decreased duration of PE, relapse rate, and increased duration of remission in patients with TTP.

UR - http://www.scopus.com/inward/record.url?scp=84893786247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893786247&partnerID=8YFLogxK

U2 - 10.1155/2013/195746

DO - 10.1155/2013/195746

M3 - Article

AN - SCOPUS:84893786247

VL - 2013

JO - Advances in Hematology

JF - Advances in Hematology

SN - 1687-9104

M1 - 195746

ER -